BRISTOL-MYERS SQUIBB COMPANY Available-for-sale Securities, Amortized Cost Basis
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Available-for-sale Securities, Amortized Cost Basis of $3.81 billion as of 2019-12-31, per its 10-K filed 2020-02-24.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2020-02-24
- 2019-12-31: Available-for-sale Securities, Amortized Cost Basis $3.81B.
- 2018-12-31: Available-for-sale Securities, Amortized Cost Basis $3.66B.
- 2018-09-30: Available-for-sale Securities, Amortized Cost Basis $3.34B.
- 2018-06-30: Available-for-sale Securities, Amortized Cost Basis $3.10B.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2019-12-31 | $3.81B 10-K · filed 2020-02-24 | |
| 2018-12-31 | $3.66B 10-K · filed 2020-02-24 | |
| 2018-09-30 | $3.34B 10-Q · filed 2018-10-25 | |
| 2018-06-30 | $3.10B 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $3.59B 10-Q · filed 2018-04-26 | |
| 2017-12-31 | $3.78B 10-K · filed 2019-02-25 | |
| 2017-09-30 | $4.92B 10-Q · filed 2017-10-26 | |
| 2017-06-30 | $5.54B 10-Q · filed 2017-07-27 | |
| 2017-03-31 | $4.79B 10-Q · filed 2017-04-27 | |
| 2016-12-31 | $4.75B 10-K · filed 2018-02-13 | |
| 2016-09-30 | $5.05B 10-Q · filed 2016-10-27 | |
| 2016-06-30 | $4.88B 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $5.29B 10-Q · filed 2016-04-28 | |
| 2015-12-31 | $6.52B 10-K · filed 2017-02-21 | |
| 2015-09-30 | $6.02B 10-Q · filed 2015-10-27 | |
| 2015-06-30 | $5.83B 10-Q · filed 2015-07-23 | |
| 2015-03-31 | $5.45B 10-Q · filed 2015-04-28 | |
| 2014-12-31 | $6.16B 10-K · filed 2016-02-12 | |
| 2014-09-30 | $6.58B 10-Q · filed 2014-10-24 | |
| 2014-06-30 | $6.66B 10-Q · filed 2014-07-24 | |
| 2014-03-31 | $5.23B 10-Q · filed 2014-04-29 | |
| 2013-12-31 | $4.53B 10-K · filed 2015-02-13 | |
| 2013-09-30 | $4.52B 10-Q · filed 2013-10-23 | |
| 2013-06-30 | $4.17B 10-Q · filed 2013-07-25 | |
| 2013-03-31 | $4.33B 10-Q · filed 2013-04-25 | |
| 2012-12-31 | $4.52B 10-K · filed 2014-02-14 | $4.62B 10-K · filed 2013-02-15 |
| 2012-09-30 | $5.03B 10-Q · filed 2012-10-24 | |
| 2012-06-30 | $5.90B 10-Q · filed 2012-07-25 | |
| 2012-03-31 | $6.25B 10-Q · filed 2012-04-26 | |
| 2011-12-31 | $5.80B 10-K · filed 2013-02-15 | |
| 2011-09-30 | $6.48B 10-Q · filed 2011-10-27 | |
| 2011-06-30 | $6.68B 10-Q · filed 2011-07-28 | |
| 2010-12-31 | $4.92B 10-K · filed 2012-02-17 | |
| 2010-09-30 | $776.00M 10-Q · filed 2010-10-26 | |
| 2009-12-31 | $831.00M 10-Q · filed 2010-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |